Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Mar 08, 2018
Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook
Achieved $1.9M Profit in the Fourth Quarter; Reported Net Loss of $3.9M for the Full Year
Delivered $0.4M Full-year Profit on a Non-GAAP Basis Excluding Business Development Transaction Costs
Delivered 7 Percent Test Growth and 6 Percent Revenue Growth in the Fourth Quarter
Guides to Double-digit Revenue Growth and Full-year Profitability in 2018
Feb 26, 2018
Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test to Predict Treatment Response in Metastatic Disease
New Liquid Biopsy Test Helps Physicians Select Most Effective Treatment, Prolonging Lives of Men with Metastatic Castration-resistant Prostate Cancer
Feb 22, 2018
Genomic Health to Announce Fourth Quarter and Year-End 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018
REDWOOD CITY, Calif. , Feb. 22, 2018 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, March 8 at 8:30 a.m. Eastern Time to discuss its fourth quarter and year-end 2017 financial results. The call and webcast
Feb 05, 2018
Oncotype DX® Genomic Prostate Score™ Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care
Unprecedented Study of Nearly 10,000 Patient Medical Records from Large Private U.S. Health Insurer Published in Reviews in Urology
Dec 21, 2017
Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif. , Dec. 21, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at the 36 th Annual J.P. Morgan Healthcare Conference at the Westin St.
Dec 11, 2017
Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum
New Data Supports Expanded Use of Oncotype DX Breast Recurrence Score® Test for Predicting Treatment Benefit in Neoadjuvant Setting
Large Study Demonstrates Excellent Survival without Chemotherapy in Certain Node-positive Patients with Low Recurrence Score Test Results
Dec 06, 2017
Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug Development
Additionally, Genomic Health Makes a $4M Equity Investment in Biocartis, Furthering Collaboration to Develop an IVD version of the Oncotype DX Breast Recurrence Score® Test
Nov 30, 2017
Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging
REDWOOD CITY, Calif. , Nov. 30, 2017 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that it will present 10 Oncotype DX ®  studies at the 40 th  San Antonio Breast Cancer Symposium (SABCS), which is being held December 5-9, 2017.
Nov 28, 2017
Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests
Global Licensing Agreement Provides Genomic Health with Exclusive Rights to Cleveland Diagnostics' Proprietary IsoPSA™ Technology
Nov 21, 2017
Genomic Health to Present at the 29th Annual Piper Jaffray Healthcare Conference
REDWOOD CITY, Calif. , Nov. 21, 2017 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 29 th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 at 10:30 a.m. Eastern Time .